Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.25.1 (
proteasome
)
28,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The ubiquitin ligase
CBLL1
(also known as HAKAI) has been proposed to be a critical cellular factor exploited by West Nile virus (WNV) for productive infection.
CBLL1
has emerged as a major hit in a recent RNA interference screen designed to identify cellular factors required for the early stages of the WNV life cycle. Follow-up experiments showed that HeLa cells knocked down for
CBLL1
by a small interfering RNA (siRNA) failed to internalize WNV particles and resisted infection. Furthermore, depletion of a free-ubiquitin pool by the proteasome inhibitor MG132 abolished WNV endocytosis, suggesting that
CBLL1
acts in concert with the ubiquitin
proteasome
system to mediate virus internalization. Here, we examined the effect of
CBLL1
knockdown and
proteasome
inhibitors on infection by WNV and other flaviviruses. We identified new siRNAs that repress the
CBLL1 protein
and strongly inhibit the endocytosis of Listeria monocytogenes, a bacterial pathogen known to require
CBLL1
to invade host cells. Strikingly, however, we detected efficient WNV, dengue virus, and yellow fever virus infection of human cells, despite potent downregulation of
CBLL1
by RNA interference. In addition, we found that the
proteasome
inhibitors MG132 and lactacystin did not affect WNV internalization but strongly repressed flavivirus RNA translation and replication. Together, these data do not support a requirement for
CBLL1
during flavivirus entry and rather suggest an essential role of the ubiquitin/
proteasome
pathway for flavivirus genome amplification.
...
PMID:Appraising the roles of CBLL1 and the ubiquitin/proteasome system for flavivirus entry and replication. 2119 Oct 16